MannKind Corporation Share Price Nasdaq
Stocks
US56400P2011
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| Market Cap | 1.25B 1.1B 1.02B 935M 1.76B 121B 1.79B 12.13B 4.75B 59.06B 4.7B 4.6B 204B | P/E 2026 * |
-142x | P/E 2027 * | 28.7x |
|---|---|---|---|---|---|
| Enterprise Value | 1.25B 1.1B 1.02B 935M 1.76B 121B 1.79B 12.13B 4.75B 59.06B 4.7B 4.6B 204B | EV / Sales 2026 * |
2.7x | EV / Sales 2027 * | 2.4x |
| Free-Float |
98.46% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: MannKind Corporation
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Castagna
CEO | Chief Executive Officer | 49 | 24/05/2017 |
| Director of Finance/CFO | 50 | 21/04/2024 | |
Ajay Ahuja
CTO | Chief Tech/Sci/R&D Officer | - | 28/09/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Ronald Consiglio
BRD | Director/Board Member | 82 | 30/09/2003 |
Michael Friedman
BRD | Director/Board Member | 82 | 30/11/2003 |
James Shannon
CHM | Chairman | 69 | 08/12/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.80% | -0.83% | +52.79% | +86.50% | 55.57B | |
| -0.45% | +0.67% | +55.19% | +57.78% | 54.26B | |
| +0.49% | +1.05% | -16.58% | -13.15% | 23.35B | |
| -0.97% | -1.76% | +4.82% | +427.27% | 23.54B | |
| +0.05% | -1.77% | +38.71% | -4.22% | 20.32B | |
| +2.31% | +0.21% | +37.18% | -29.47% | 17.36B | |
| +1.08% | -3.63% | +36.77% | +547.87% | 15.59B | |
| 0.00% | -2.08% | +165.40% | +297.92% | 14.96B | |
| -0.73% | +0.19% | +25.15% | +179.81% | 14.11B | |
| Average | +0.36% | -1.07% | +44.38% | +172.26% | 26.56B | |
| Weighted average by Cap. | +0.42% | -1.21% | +43.88% | +136.51% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 463M 406M 376M 346M 653M 44.58B 660M 4.49B 1.76B 21.85B 1.74B 1.7B 75.44B | 522M 457M 424M 390M 735M 50.23B 744M 5.06B 1.98B 24.62B 1.96B 1.92B 85B |
| Net income | 72K 63.11K 58.47K 53.82K 101K 6.93M 103K 698K 273K 3.4M 270K 264K 11.73M | 56.82M 49.8M 46.15M 42.47M 80.09M 5.47B 81.06M 551M 216M 2.68B 213M 209M 9.26B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
